Immunocore Holdings (IMCR) Capital Expenditures Growth (1y) (2022 - 2026)

Immunocore Holdings (IMCR) Capital Expenditures Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (1y) (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn - 38.18%
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.75 Bn 467.96 Bn 1.35 Bn -27.93%
5 Vertex Pharmaceuticals 122.14 Bn 114.89 Bn 2.59 Bn 227.76%
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn 0.57%
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.94 Bn 50.76 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn 143.40%
10 Immunocore Holdings 1.75 Bn 909.19 Mn 106.24 Mn 497.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 497.65%
Dec 31, 2025 -19.64%
Sep 30, 2025 -9.66%
Jun 30, 2025 25.08%
Mar 31, 2025 -30.70%
Dec 31, 2024 338.68%
Sep 30, 2024 290.57%
Jun 30, 2024 -76.27%
Mar 31, 2024 -85.67%
Dec 31, 2023 -24.12%
Sep 30, 2023 -54.34%
Dec 31, 2022 187.33%